Overview

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib
Mitogens